LOGC LogicBio Therapeutics Inc.

3.92
+0.03  (+1%)
Previous Close 3.9
Open 3.88
52 Week Low 3.7204
52 Week High 9.745
Market Cap $126,542,922
Shares 32,240,235
Float 22,701,642
Enterprise Value $77,518,549
Volume 56,734
Av. Daily Volume 83,993
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
LB-001 - (SUNRISE)
Methylmalonic Acidemia (MMA)
Phase 1/2
Phase 1/2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Latest News

  1. LEXINGTON, Mass., Oct. 21, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company, today is slated to present new preclinical data on its GeneRide™ platform at the European Society of Gene and Cell Therapy (ESGCT) Virtual Congress 2021, taking place October 19-22, 2021. The newly presented preclinical data further validate previous research in methylmalonic acidemia (MMA) and highlight selective advantage, a key feature of the GeneRide technology, in two additional indications characterized by intrinsic liver damage, hereditary tyrosinemia type 1 (HT1) and Wilson disease. Selective advantage enables edited hepatocytes carrying the corrective gene to survive and reproduce better than the endogenous…

    LEXINGTON, Mass., Oct. 21, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company, today is slated to present new preclinical data on its GeneRide™ platform at the European Society of Gene and Cell Therapy (ESGCT) Virtual Congress 2021, taking place October 19-22, 2021. The newly presented preclinical data further validate previous research in methylmalonic acidemia (MMA) and highlight selective advantage, a key feature of the GeneRide technology, in two additional indications characterized by intrinsic liver damage, hereditary tyrosinemia type 1 (HT1) and Wilson disease. Selective advantage enables edited hepatocytes carrying the corrective gene to survive and reproduce better than the endogenous mutated hepatocytes and to ultimately repopulate a part or whole of the diseased liver.

    The data presented at ESGCT highlighted mouse models of the three liver indications treated with GeneRide vectors to deliver corrective genes. In all these models, expansion of the corrected healthy hepatocytes correlated with improved diseased markers.

    In the HT1 models with acute liver damage, the data showed that GeneRide-corrected hepatocytes repopulated the entire liver within four weeks post-administration, replacing the diseased hepatocytes with corrected hepatocytes. HT1 mice are deficient in the gene encoding fumarylacetoacetate hydrolase (FAH), which is required to metabolize the amino acid tyrosine, resulting in the accumulation of toxic metabolites. HT1 mice that received the GeneRide-FAH vector were no longer reliant on the current standard of care for the disease, and demonstrated restored normal body growth, liver function, and undetectable succinyl acetone levels, one of the toxic metabolites that accumulates in patients with HT1. Compared to the current standard of care, treatment with the GeneRide vector resulted in superior succinyl acetone reduction and lower alfa-fetoprotein levels, a clinically validated biomarker for hepatocellular carcinoma and another risk factor for untreated HT1 patients.

    Wilson disease results from a defect in copper transport, leading to toxic accumulation of copper and damage to tissues. In a Wilson disease mouse model, GeneRide-corrected hepatocytes repopulated the liver over time, and treated mice showed improvements in liver function, hepatomegaly, and urinary copper excretion.

    "We are very excited to present these preclinical data in HT1 and Wilson disease. These data demonstrated repopulation of a diseased liver using our in vivo genome editing technology, resulting in GeneRide-edited corrected hepatocytes. The results in HT1 were particularly encouraging, demonstrating complete liver repopulation after treatment. These data further validate our technology and represent an important step as we continue on our mission to deliver the hope of genetic medicine to people impacted by devastating diseases," said Mariana Nacht, Ph.D., chief scientific officer of LogicBio.

    Shengwen Zhang, director, molecular and cellular pharmacology at LogicBio, will give an oral presentation highlighting GeneRide's successful delivery of corrective genes in HT1, Wilson disease and MMA. Selective advantage and expansion of corrected hepatocytes was observed in these preclinical models, demonstrated by detection of increasing levels of a tagged albumin protein, albumin-2A, a technology-related biomarker indicating site-specific gene insertion and protein expression, as well as immunohistochemistry for the corrective protein in liver sections. Results also showed increasing levels of albumin-2A correlated with increased expression of the corrective gene and improved disease burden. The company believes that these data support the development of GeneRide vectors to durably treat multiple genetic diseases with liver dysfunction.

    Additional posters presented at ESGCT highlight the Company's adeno-associated virus (AAV) technology platform advancements. One poster detailed the combination of LogicBio's proprietary plasmids and optimized transfection process in suspension HEK293 cells, which resulted in a 10- to 25-fold increase in titers using an LK03 capsid in 50L bioreactors. A separate poster highlighted recent development of anion exchange (AEX)-based high-pressure liquid chromatography, allowing LogicBio to use an analytical method to measure the percentage of full capsids in any given sample of AAV-LK03.

    Additional information on the meeting can be found on the ESGCT website.

    The oral presentation and posters will be made available on the Presentations section of the Company website at https://investor.logicbio.com/events-and-presentations/presentations.

    About LogicBio Therapeutics 

    LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. The company's genome editing platform, GeneRide™, is a new approach to precise gene insertion harnessing a cell's natural DNA repair process potentially leading to durable therapeutic protein expression levels. The company's gene delivery platform, sAAVy™, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a broad range of indications and tissues. The company is based in Lexington, MA. For more information, visit www.logicbio.com, which does not form a part of this release.

    Forward-Looking Statements

    Statements in this press release regarding LogicBio's strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, including but not limited to statements regarding validation of previous research; the potential of the GeneRide™ platform; and the company's belief that preclinical data supports the development of GeneRide vectors to durably treat multiple genetic diseases with liver dysfunction. The terms "believe," "validate" and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including the risk that existing preclinical data may not be predictive of the results of ongoing or later preclinical and/or clinical results; the potential direct or indirect impact of the COVID-19 pandemic on our business, operations, and the markets and communities in which we and our partners, collaborators and vendors operate; manufacturing risks; risks associated with management and key personnel changes and transitional periods; the actual funding required to develop and commercialize product candidates, including for safety, tolerability, enrollment, manufacturing or economic reasons; the timing and content of decisions made by regulatory authorities; the actual time it takes to initiate and complete preclinical and clinical studies; the competitive landscape; changes in the economic and financial conditions of LogicBio; and LogicBio's ability to obtain, maintain and enforce patent and other intellectual property protection for LB-001 and any other product candidates. Other risks and uncertainties include those identified under the heading "Risk Factors" in LogicBio's Annual Report on Form 10-K for the year ended December 31, 2020 and other filings that LogicBio may make with the U.S. Securities and Exchange Commission in the future. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release, and LogicBio does not undertake, and specifically disclaims, any obligation to update any forward-looking statements contained in this press release.

    Investor Contacts

    Laurence Watts

    Gilmartin Group

    (619) 916-7620

    laurence@gilmartinir.com 

    Stephen Jasper

    Gilmartin Group

    (858) 525-2047

    stephen@gilmartinir.com 

    Media Contacts:

    Jenna Urban

    Berry & Company Public Relations

    W: 212-253-8881

    C: 203-218-9180

    jurban@berrypr.com

    Bill Berry

    Berry & Company Public Relations

    W: 212-253-8881

    C: 917-846-3862

    bberry@berrypr.com

     

    Cision View original content:https://www.prnewswire.com/news-releases/logicbio-therapeutics-announces-successful-repopulation-of-diseased-livers-in-mice-with-healthy-corrected-hepatocytes-in-two-new-indications-using-generide-genome-editing-technology-301405605.html

    SOURCE LogicBio Therapeutics, Inc.

    View Full Article Hide Full Article
  2. LEXINGTON, Mass., Oct. 18, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company, today announced clinical trial results demonstrating the first-ever in vivo genome editing in children. Early data from the company's Phase 1/2 SUNRISE clinical trial showed measurable levels of albumin-2A, a technology-related biomarker indicating site-specific gene insertion and protein expression. The SUNRISE trial is evaluating the safety, tolerability and preliminary efficacy of LB-001, the company's investigational, single-administration genome editing therapy, in pediatric patients with methylmalonic acidemia (MMA).

    These results follow a recommendation from the independent Data Safety Monitoring Board…

    LEXINGTON, Mass., Oct. 18, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company, today announced clinical trial results demonstrating the first-ever in vivo genome editing in children. Early data from the company's Phase 1/2 SUNRISE clinical trial showed measurable levels of albumin-2A, a technology-related biomarker indicating site-specific gene insertion and protein expression. The SUNRISE trial is evaluating the safety, tolerability and preliminary efficacy of LB-001, the company's investigational, single-administration genome editing therapy, in pediatric patients with methylmalonic acidemia (MMA).

    These results follow a recommendation from the independent Data Safety Monitoring Board (DSMB) overseeing the SUNRISE trial to continue the study without modification. The DSMB's recommendation was based on an evaluation of the safety data from the first two patients enrolled in the trial. Per the FDA-cleared protocol, albumin-2A detection together with the DSMB continuation recommendation enables LogicBio to begin enrolling two patients in the higher dose (1 x 1014 vg/kg) cohort (with ages ranging three to twelve years old) and two patients in the lower age (six months to two years old) cohort at the lower dose (5 x 1013 vg/kg) of LB-001.

    "We are very excited to have achieved this significant milestone in the field of genetic medicine," said Fred Chereau, president and chief executive officer of LogicBio. "These early data indicate that we can precisely edit hepatocytes in vivo to treat a genetic liver disease with a single intravenous infusion using our proprietary GeneRide™ technology. Today's announcement is a demonstration that homologous recombination genome editing without the use of nucleases is a potential alternative to genome editing technologies in development that use nucleases, such as CRISPR. The ability to insert the correct version of a gene in a cell's genome without nucleases is an important step to unlocking the potential of GeneRide™ to treat a larger number of genetic diseases."

    SUNRISE is a first-in-human, open-label, multi-center, Phase 1/2 clinical trial designed to assess the safety and tolerability of a single intravenous infusion of LB-001 in pediatric patients with MMA. LB-001 is designed to non-disruptively insert a corrective copy of the MMUT gene into the albumin locus to drive lifelong therapeutic levels of MMUT expression in the liver. LB-001 is based on the company's proprietary GeneRide technology, which uses homologous recombination, a natural DNA repair process, to enable precise editing of the genome without the need for exogenous nucleases and promoters that have been associated with an increased risk of immune response and cancer.

    "MMA is a rare, life-threatening genetic disorder for which there are no treatments addressing the underlying cause of the disease. By demonstrating for the first time ever that in vivo, nuclease-free genome editing in pediatric patients is achievable, we are one step closer to bringing a safe and effective genetic medicine to children suffering from MMA and, potentially, other early onset genetic diseases where early intervention is critical to achieve optimal health outcomes," said Daniel Gruskin, MD, chief medical officer of LogicBio. "I would like to thank the patients, their families and the investigators who are participating in this landmark trial. We look forward to continuing to progress the clinical study to better understand the biochemical and clinical effect of this genome editing therapy."

    The Company remains on track to present additional interim data by the end of 2021.

    About the SUNRISE Trial

    The SUNRISE trial is an open-label, multi-center, Phase 1/2 clinical trial designed to assess the safety and tolerability of a single intravenous infusion of LB-001 in pediatric patients with methylmalonic acidemia (MMA) characterized by methylmalonyl-CoA mutase gene (MMUT) mutations. Seven leading centers in the United States and one in Saudi Arabia are expected to participate in the trial. With the aim of evaluating LB-001 at an early age, the SUNRISE trial initially enrolled 3-12 year old patients and, following a recommendation from the trial's independent Data Safety Monitoring Board and detection of a biomarker indicating site-specific gene insertion, is permitted to enroll infants as young as 6 months old. The SUNRISE trial is designed to enroll up to 8 patients and evaluate a single administration of LB-001 at two dose levels.

    About LB-001

    LB-001 is an investigational, first-in-class, single-administration, genome editing therapy for early intervention in methylmalonic acidemia (MMA) using LogicBio's proprietary GeneRide™ drug development platform. GeneRide technology utilizes a natural DNA repair process called homologous recombination that enables precise editing of the genome without the need for exogenous nucleases and promoters that have been associated with an increased risk of immune response and cancer. LB-001 is designed to non-disruptively insert a corrective copy of the methylmalonyl-CoA mutase (MMUT) gene into the albumin locus to drive lifelong therapeutic levels of MMUT expression in the liver, the main site of MMUT expression and activity. LB-001 is delivered to hepatocytes intravenously via liver-targeted, engineered recombinant adeno-associated virus vector (rAAV-LK03). Preclinical studies found that LB-001 was safe and demonstrated transduction of hepatocytes, site-specific genomic integration, and transgene expression. LB-001–corrected hepatocytes in a mouse model of MMA demonstrated preferential survival and expansion (selective advantage), thus contributing to a progressive increase in hepatic MMUT expression over time. LB-001 resulted in improved growth, metabolic stability, and survival in MMA mice. The U.S. Food and Drug Administration (FDA) granted fast track designation, rare pediatric disease designation and orphan drug designation for LB-001 for the treatment of MMA. In addition, the European Medicines Agency (EMA) granted orphan drug designation for LB-001 for the treatment of MMA.

    About Methylmalonic Acidemia (MMA)

    Methylmalonic acidemia (MMA) is a rare and life-threatening genetic disorder affecting approximately 1 in 50,000 newborns in the United States. In the most common form of MMA, a mutation in a gene called methylmalonyl-CoA mutase (MMUT) prevents the body from properly processing certain fats and proteins. As a result, toxic metabolites accumulate in the liver, in muscle tissue and in the brain. Symptoms include vomiting, lethargy, seizures, developmental delays and organ damage. There is no approved medical therapy addressing the underlying cause of the disease. To manage the symptoms, patients go on a severely restrictive, low-protein, high-calorie diet, often through a feeding tube. Even with aggressive management, these patients often experience life-threatening metabolic crises that can require recurrent hospitalizations and cause permanent neurocognitive damage. Because of this risk for irreversible damage, early intervention is critical and newborns are screened for MMA in every state in the United States.

    About LogicBio Therapeutics 

    LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. The Company's genome editing platform, GeneRide™, is a new approach to precise gene insertion harnessing a cell's natural DNA repair process potentially leading to durable therapeutic protein expression levels. The Company's gene delivery platform, sAAVy™, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a broad range of indications and tissues. The Company is based in Lexington, MA. For more information, visit www.logicbio.com, which does not form a part of this release.

    Forward-Looking Statements

    Statements in this press release regarding LogicBio's strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, including but not limited to statements regarding early clinical results and the significance and interpretation thereof; homologous recombination genome editing without the use of nucleases as a potential alternative to genome editing technologies in development that use nucleases, such as CRISPR; the potential of the GeneRide™ platform, including the potential for genetic medicines based on the platform to be treatment options for genetic diseases; progressing the SUNRISE trial; the expected timing of announcing additional interim clinical data in the SUNRISE trial; the potential benefits of LB-001; and the sites expected to participate in the SUNRISE trial. The terms "demonstrating," "indicate," "look forward," "on track," "potential" and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including the risk that existing preclinical and clinical data, including early clinical data from a trial, may not be predictive of the results of ongoing or later clinical trials; the risk that clinical trials may not be successful or may be discontinued or delayed for any reason; the potential direct or indirect impact of the COVID-19 pandemic on our business, operations, and the markets and communities in which we and our partners, collaborators and vendors operate; manufacturing risks; risks associated with management and key personnel changes and transitional periods; the actual funding required to develop and commercialize product candidates, including for safety, tolerability, enrollment, manufacturing or economic reasons; the timing and content of decisions made by regulatory authorities; the actual time it takes to initiate and complete preclinical and clinical studies; the competitive landscape; changes in the economic and financial conditions of LogicBio; and LogicBio's ability to obtain, maintain and enforce patent and other intellectual property protection for LB-001 and any other product candidates. Other risks and uncertainties include those identified under the heading "Risk Factors" in LogicBio's Annual Report on Form 10-K for the year ended December 31, 2020 and other filings that LogicBio may make with the U.S. Securities and Exchange Commission in the future. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release, and LogicBio does not undertake, and specifically disclaims, any obligation to update any forward-looking statements contained in this press release.

    Investor Contacts

    Laurence Watts 

    Gilmartin Group 

    (619) 916-7620 

    laurence@gilmartinir.com 

    Stephen Jasper 

    Gilmartin Group 

    (858) 525-2047 

    stephen@gilmartinir.com 

    Media Contacts:

    Jenna Urban 

    Berry & Company Public Relations 

    W: 212-253-8881 

    C: 203-218-9180 

    jurban@berrypr.com

    Bill Berry 

    Berry & Company Public Relations 

    W: 212-253-8881 

    C: 917-846-3862 

    bberry@berrypr.com

     

    Cision View original content:https://www.prnewswire.com/news-releases/logicbio-therapeutics-announces-early-clinical-trial-results-demonstrating-first-ever-in-vivo-genome-editing-in-children-301402102.html

    SOURCE LogicBio Therapeutics, Inc.

    View Full Article Hide Full Article
  3. LEXINGTON, Mass., Oct. 12, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that it was selected to present new data from the company's GeneRide™ platform in a plenary oral presentation and three poster presentations at the upcoming European Society of Gene and Cell Therapy (ESGCT) Virtual Congress 2021, to be held from October 19-22, 2021.

    The oral presentation will include new preclinical GeneRide data showing delivery of corrective genes in three different indications with intrinsic liver damage demonstrating strong evidence of selective advantage…

    LEXINGTON, Mass., Oct. 12, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that it was selected to present new data from the company's GeneRide™ platform in a plenary oral presentation and three poster presentations at the upcoming European Society of Gene and Cell Therapy (ESGCT) Virtual Congress 2021, to be held from October 19-22, 2021.

    The oral presentation will include new preclinical GeneRide data showing delivery of corrective genes in three different indications with intrinsic liver damage demonstrating strong evidence of selective advantage of the corrected hepatocytes. Poster presentations will highlight GeneRide expression data in preclinical models of tyrosinemia type 1, as well as the company's optimized adeno-associated virus (AAV) process development.

    Oral Presentation Details:

    Title: Nuclease-free, promoterless recombinant AAV-mediated genome editing restores function of hepatocytes leading to selective advantage and repopulation in mouse models with liver disease (OR40)

    Presenter: Shengwen Zhang, Director, Pharmacology, LogicBio Therapeutics

    Session: 5b: Gene Editing III

    Session date/time: October 21, 2021, 17:00-17:15 p.m. CEST (11:00-11:15 a.m. ET)

    Poster Presentations Details:

    Title: A novel endonuclease-free genome editing technology to edit hepatocytes in vivo led to a full molecular liver transplant and cured mice in preclinical models of Tyrosinemia Type 1 (P253)

    Q. Qiang Xiong, Director, Head of Preclinical Pharmacology, LogicBio Therapeutics

    Title: Development of an Anion Exchange Chromatography Method to Assess Percent Full Capsids for Chimeric Capsid AAV-LK03 (P268)

    William Lee, Research Associate, LogicBio Therapeutics

    Title: Modified plasmid and transfection optimization in suspension HEK293 cells lead to scalable high-yield process for AAV manufacturing (P278)

    Hans Reuter, Upstream Engineer, Process Development, LogicBio Therapeutics

    Additional information on the meeting can be found on the ESGCT website.

    The presentation and posters will be available shortly after being presented on the LogicBio Therapeutics website at Presentations | LogicBio Therapeutics, Inc.

    About LogicBio Therapeutics 

    LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. The Company's gene editing platform, GeneRide™, is a new approach to precise gene insertion harnessing a cell's natural DNA repair process potentially leading to durable therapeutic protein expression levels. The Company's gene delivery platform, sAAVy™, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a broad range of indications and tissues. The Company is based in Lexington, MA. For more information, visit www.logicbio.com, which does not form a part of this release.

    Investor Contacts

    Laurence Watts

    Gilmartin Group

    (619) 916-7620

    laurence@gilmartinir.com 

    Stephen Jasper

    Gilmartin Group

    (858) 525-2047

    stephen@gilmartinir.com 

    Media Contacts:

    Adam Daley

    Berry & Company Public Relations

    W:212-253-8881

    C: 614-580-2048

    adaley@berrypr.com 

    Jenna Urban

    Berry & Company Public Relations

    W: 212-253-8881

    C: 203-218-9180

    jurban@berrypr.com 

    Cision View original content:https://www.prnewswire.com/news-releases/logicbio-therapeutics-to-present-new-generide-data-at-the-european-society-of-gene-and-cell-therapy-virtual-congress-2021-301398543.html

    SOURCE LogicBio Therapeutics, Inc.

    View Full Article Hide Full Article
  4. LEXINGTON, Mass., Sept. 24, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that president and chief executive officer, Fred Chereau, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 8:00 a.m. ET.

    A live webcast of the fireside chat will be made available on the Investors section of the Company's website at www.logicbio.com/investors. The webcast replay will be available for approximately 30 days.

    About LogicBio Therapeutics 
    LogicBio Therapeutics is a clinical-stage genetic…

    LEXINGTON, Mass., Sept. 24, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that president and chief executive officer, Fred Chereau, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 8:00 a.m. ET.

    A live webcast of the fireside chat will be made available on the Investors section of the Company's website at www.logicbio.com/investors. The webcast replay will be available for approximately 30 days.

    About LogicBio Therapeutics 

    LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. The Company's gene editing platform, GeneRide™, is a new approach to precise gene insertion harnessing a cell's natural DNA repair process potentially leading to durable therapeutic protein expression levels. The Company's gene delivery platform, sAAVy™, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a broad range of indications and tissues. The Company is based in Lexington, MA. For more information, visit www.logicbio.com, which does not form a part of this release.

    Investor Contacts

    Laurence Watts

    Gilmartin Group

    (619) 916-7620

    laurence@gilmartinir.com 

    Stephen Jasper

    Gilmartin Group

    (858) 525-2047

    stephen@gilmartinir.com 

    Media Contacts:

    Adam Daley

    Berry & Company Public Relations

    W: 212-253-8881

    C: 614-580-2048

    adaley@berrypr.com 

    Jenna Urban

    Berry & Company Public Relations

    W: 212-253-8881

    C: 203-218-9180

    jurban@berrypr.com 

    Cision View original content:https://www.prnewswire.com/news-releases/logicbio-therapeutics-to-participate-in-the-2021-cantor-virtual-global-healthcare-conference-301384769.html

    SOURCE LogicBio Therapeutics, Inc.

    View Full Article Hide Full Article
  5. LEXINGTON, Mass., Sept. 10, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that president and chief executive officer Fred Chereau will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021. The on-demand presentation will be available at 7:00 a.m. ET on Monday, September 13, 2021.

    About LogicBio Therapeutics 
    LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through…

    LEXINGTON, Mass., Sept. 10, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that president and chief executive officer Fred Chereau will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021. The on-demand presentation will be available at 7:00 a.m. ET on Monday, September 13, 2021.

    About LogicBio Therapeutics 

    LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. The Company's gene editing platform, GeneRide™, is a new approach to precise gene insertion harnessing a cell's natural DNA repair process potentially leading to durable therapeutic protein expression levels. The Company's gene delivery platform, sAAVy™, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a broad range of indications and tissues. The Company is based in Lexington, MA. For more information, visit www.logicbio.com, which does not form a part of this release.

    Investor Contacts

    Laurence Watts

    Gilmartin Group

    (619) 916-7620

    laurence@gilmartinir.com

    Stephen Jasper

    Gilmartin Group

    (858) 525-2047

    stephen@gilmartinir.com

    Media Contacts:

    Adam Daley

    Berry & Company Public Relations

    W:212-253-8881

    C: 614-580-2048

    adaley@berrypr.com

    Jenna Urban

    Berry & Company Public Relations

    W: 212-253-8881

    C: 203-218-9180

    jurban@berrypr.com

     

    Cision View original content:https://www.prnewswire.com/news-releases/logicbio-therapeutics-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference-301373192.html

    SOURCE LogicBio Therapeutics, Inc.

    View Full Article Hide Full Article
View All LogicBio Therapeutics Inc. News